The Weekly Litigation News Digest is now live. Subscribe now

IP Verse

Gastrin Antagonists (Eg Yf476, Netazepide) For Treatment And Prevention Of Osteoporosis - EP3071206

The patent EP3071206 was granted to CL Biosciences on Feb 17, 2021. The application was originally filed on Nov 21, 2014 under application number EP14815149A. The patent is currently recorded with a legal status of "Granted And Under Opposition".

EP3071206

CL BIOSCIENCES
Application Number
EP14815149A
Filing Date
Nov 21, 2014
Status
Granted And Under Opposition
Jan 15, 2021
Publication Date
Feb 17, 2021
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

TRIO MEDICINESNov 17, 2021HARRISWITHDRAWN

Patent Citations (7) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication Number
INTERNATIONAL-SEARCH-REPORTWO2005007107
INTERNATIONAL-SEARCH-REPORTWO9312817
OPPOSITIONUS2003119896
OPPOSITIONUS5952511
OPPOSITIONWO2005007107
OPPOSITIONWO9312817
OPPOSITIONWO9419322

Dossier Documents

The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents